studying repeated dce-mri and dwi in patients diagnosed with prostate cancer

Conditions: Prostate Cancer

Summary: rationale: diagnostic procedures, such as dynamic contrast-enhanced magnetic resonance imaging or dce-mri and diffusion-weighted imaging or dwi, may provide images of prostate cancer or any cancer that remains after biopsy. purpose: this trial studies repeated dce-mri and dwi in patients diagnosed with prostate cancer.

objectives: primary * determine the test-retest performance, assessed by the repeatability coefficient \[rc\] of k\^trans and gadolinium curve (iaugc90\^bn) and measured by median pixel values of the whole prostate. * determine the test-retest performance, assessed by the rc of diffusion-weighted imaging (dwi) metrics d(t) and measured by median pixel values of the whole prostate. secondary * determine the test-retest performance, assessed by rc of k\^trans, iaugc90\^bn, and d(t), and measured by median pixel values of the dominant prostate tumor. * determine the effect of reader on the rc of dynamic contrast-enhanced magnetic resonance imaging (dce-mri) and dwi metrics for whole prostate and tumor nodule target lesion. * determine whether t1-dependent or t1-independent methods for gadolinium quantification in dce-mri studies produce differing values for the rc for k\^trans and iaugc90\^bn. * explore the correlation between dce-mri and dwi metrics for both whole prostate and dominant tumor nodule as target lesions. (exploratory) * determine whether the "coffee break" approach toward test-retest analysis of quantitative dwi provides a reasonable estimate of the rc of d(t)of the whole prostate, using as the gold standard the rc of d(t) obtained between the two separate mri visits. (exploratory) outline: this is a multicenter study. patients are stratified according to mri vendor used (siemens vs ge vs philips). patients receive gadolinium-based contrast iv and undergo dce-mri\* and dwi 2 imaging at 2-14 days apart prior to treatment initiation. a central reader evaluation of the 2 successive scans is then conducted. note: \*at the discretion of the participating sites, the initial mri visit (mri scan 1) may be supplemented with endorectal-coil imaging per institutional norms.

Eligibility criteria:
disease characteristics: * diagnosis of prostate adenocarcinoma by transrectal ultrasound (trus)-guided biopsy between 28 to 90 days prior to enrollment * minimal tumor burden as defined by at least one of the following criteria: * one single core with ≥ 50% cancer burden and ≥ 5 mm tumor length * two or more cores in the same prostate region, each with ≥ 30% cancer burden * three or more cores positive for prostate cancer (of any magnitude of cancer burden) in the same prostate region * gleason score of 7 or higher cancer burden * prostate-specific antigen (psa) ≥ 10 ng/ml patient characteristics: * able to tolerate magnetic resonance imaging (mri) required by protocol, to be performed at an american college of radiology imaging network (acrin)-qualified facility and scanner * not suitable to undergo mri or gadolinium-based contrast agent because of: * severe claustrophobia not relieved by oral anxiolytics per institutional standard practice * presence of mri-incompatible metallic objects or implanted medical devices in body (including, but not limited to, non-mri compatible metal objects, cardiac pacemaker, aneurysm clips, artificial heart valves with steel parts, or metal fragments in the eye or central nervous system) * renal failure, as determined by glomerular filtration rate (gfr) \< 30 ml/min based on a serum creatinine level obtained within 48 hours prior to enrollment * weight greater than that allowable by the mri table, per local institutional practice prior concurrent therapy: * no anti-androgenic therapy within 30 days prior to enrollment * no prior external-beam radiotherapy, proton radiotherapy, or brachytherapy to the prostate * no prior hip replacement or other major pelvic surgery

Keywords: stage iia prostate cancer stage iib prostate cancer stage iii prostate cancer stage iv prostate cancer adenocarcinoma of the prostate